- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01594385
Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients (OASIT)
Seprafilm in Open Abdomens: a Prospective Evaluation of Wound and Adhesion Characteristics in Trauma Damage Control (OASIT)
The goal of this study is to test the effects of Seprafilm adhesion barrier on patients who are undergoing open abdomen damage control management for traumatic injuries when compared to no adhesion barrier use. Specifically, the researchers wish to study the effects of Seprafilm adhesion barrier on:
- the number and intensity of adhesions,
- whether there is any difference between treatment groups (Seprafilm vs. no Seprafilm) who go on to successful definitive abdominal closure,
- rate of occurrence of secondary complications (such as abscesses) associated with short- and long-term beneficial effects of reducing adhesion formation,and
- whether there is any difference between treatment groups regarding patient functional recovery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Data to be analyzed includes:
Age, gender, traumatic injuries, trauma alert level, procedure information, length of hospital stay, length of ICU stay, interval between admission and initial operation, interval between operations, whether operation took place during the day or night, duration of operation in minutes, number of surgeons present during the operation, description of the initial operation, justification for using damage control approach, complications noted, injuries missed or delayed in diagnosis, Acute Physiology and Chronic Health Evaluation II (APACHE II) calculations at various time points, Simplified Acute Physiology Score (SAPS II) calculations at various time points, Glasgow Coma Score (GCS) calculations at various time points, changes in GCS at over time, Injury Severity Score (ISS) at various time points, Abbreviated Injury Scale (AIS) at various time points, Penetrating Abdominal Trauma Index score (if applicable) at various time points, complete blood count (CBC) results at various time points, blood chemistry results at various time points, blood gas results at various time points, subject randomization information, number of operations, adhesion scores (Zuhlke and Yaacobi) for each operative procedure, contamination score for each operative procedure, diagnosis and description of sub-procedures for each operative procedure, wound characteristics from the start and end of all operative procedures (e.g. length and width of the fascia and skin), type of abdominal coverage or closure, discharge destination (e.g. home, short term rehabilitation facility, etc.), Functional Outcome Measure score, Glasgow Outcome Score (GOS) at various time points, number and interval of post discharge follow-up visits, wound characteristics since discharge at several time points and complications/complaints noted since discharge at several time points.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, United States, 32861
- Carolinas Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Medical Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- St. Luke's Hospital
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Trauma patients undergoing DC/OA management for traumatic injury
- Age 18+
- Life expectancy longer than 48 hours
Exclusion Criteria:
- Prisoners
- Pregnant patients
- Younger than 18 years of age
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Seprafilm
The treatment group will receive Seprafilm while the control group will not receive Seprafilm.
Allocation of patients will be in 1:1 ratio.
|
Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:
|
NO_INTERVENTION: No Seprafilm
This group will be treated according to the current standard of care.
No seprafilm will be applied in this subset of patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adhesion Characteristics
Time Frame: Up to 1 year
|
Zuhlke adhesion score (1 - minimum to 4 - maximum)
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound Healing Characteristics
Time Frame: Participants will be followed until their open abdomen is closed. Depending on the nature and severity of the wound, this period may last as long as 1 year after the patient has been discharged.
|
There will not be a fixed duration of outpatient follow-up (fixed follow-up in trauma patients is not practical due to the unpredictable nature of trauma population), an average (mean) follow-up will be determined for the entire cohort of patients for the purposes of the study, up to a maximum of 1 year (if available) following hospital discharge.
|
Participants will be followed until their open abdomen is closed. Depending on the nature and severity of the wound, this period may last as long as 1 year after the patient has been discharged.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Mortality
Time Frame: 28 days & end of follow-up
|
Assessment of patient mortality at 28 days, with subsequent determination of survival (i.e., patient status at last known follow-up)
|
28 days & end of follow-up
|
Enterocutaneous and Other Fistula
Time Frame: Up to 1 year post-injury
|
Determination of enterocutaneous/other fistula among study patients during the hospitalization and the follow-up interval
|
Up to 1 year post-injury
|
Ventral Hernia
Time Frame: Up to 1 year follow-up
|
Determination of ventral hernia presence during follow-up visits
|
Up to 1 year follow-up
|
Infection / Abscess / Sepsis
Time Frame: Up to 1 year
|
Assessment of any infection, abscess, or sepsis during the initial and the follow-up periods
|
Up to 1 year
|
Bowel Obstruction
Time Frame: Up to 1 year follow-up
|
Determination of bowel obstruction during the entire available study follow-up period
|
Up to 1 year follow-up
|
Patient Functional Outcomes
Time Frame: Up to 1 year follow-up
|
Assessment of Glasgow Outcome Scale (GOS) and the Functional Outcome Measures (FOM) during the available follow-up period. FOM Source: [1] Ohio Dept of Public Safety. Ohio Trauma Registry Data Dictionary. Columbus: 2004. FOM Scale range: 1 (worst) to 4 (best); GOS Scale: 1 (worst) to 5 (best) FOM Feeding Subscale
FOM Locomotion Subscale
FOM Expression/Communication Subscale
Glasgow Outcome Scale:
|
Up to 1 year follow-up
|
Would Complication
Time Frame: Up to 1 year follow-up period
|
Tracking of wound infection, dehiscence, hernia, or any other would-related complication of complaint
|
Up to 1 year follow-up period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stanislaw P Stawicki, MD, Ohio State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009H0311
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trauma
-
Humacyte, Inc.Active, not recruitingTrauma | Trauma Injury | Trauma, Multiple | Trauma BluntUkraine
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedTrauma Injury | Trauma, MultipleTurkey
-
University Hospital, AngersRecruiting
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaRecruitingTrauma Injury | Trauma, MultipleKorea, Republic of
-
Rabin Medical CenterIsraeli Ministry of SecurityUnknown
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Chang, Steve S., M.D.Santa Barbara Cottage Hospital; Accumetrics, Inc.CompletedHead Injury Trauma BluntUnited States
-
Assistance Publique - Hôpitaux de ParisFrancophone Pediatric Resuscitation and Emergency Group (GFRUP)Completed
-
Fundacion Clinica Valle del LiliUniversity of Pittsburgh; Hospital Universitario del Valle Evaristo GarciaRecruitingTrauma | Trauma Injury | Trauma, MultipleColombia
Clinical Trials on Seprafilm
-
Nihon UniversityCompleted
-
South East Area Health Education Center, Wilmington...New Hanover Regional Medical CenterTerminated
-
National Cancer Centre, SingaporeSingapore General HospitalTerminated
-
Abington Memorial HospitalTerminatedAdhesion Formation After Primary Cesarean DeliveryUnited States
-
Genzyme, a Sanofi CompanyCompletedIntestinal Obstruction | Digestive System Surgical ProceduresUnited States, United Kingdom, Canada, Germany, Netherlands
-
University of British ColumbiaGenzyme, a Sanofi CompanyTerminatedEpithelial Ovarian CancerCanada, United States
-
University of Maryland, BaltimoreGenzyme, a Sanofi CompanyWithdrawnOpen AbdomenUnited States
-
Centre Leon BerardMinistry of Health, FranceCompletedColorectal CancerFrance
-
Weill Medical College of Cornell UniversityGenzyme, a Sanofi CompanyTerminatedIntrauterine AdhesionsUnited States
-
SciVision Biotech Inc.Taipei Veterans General Hospital, TaiwanCompletedGynecologic Surgery | Tissue AdhesionTaiwan